206 related articles for article (PubMed ID: 24909188)
1. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study.
Hyun MY; Son IP; Lee Y; Choi HG; Park KY; Li K; Kim BJ; Seo SJ; Kim MN; Hong CK
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):278-282. PubMed ID: 24909188
[TBL] [Abstract][Full Text] [Related]
2. Topical glycopyrrolate for patients with facial hyperhidrosis.
Kim WO; Kil HK; Yoon KB; Yoon DM
Br J Dermatol; 2008 May; 158(5):1094-7. PubMed ID: 18294315
[TBL] [Abstract][Full Text] [Related]
3. Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate.
Luh JY; Blackwell TA
South Med J; 2002 Jul; 95(7):756-8. PubMed ID: 12144084
[TBL] [Abstract][Full Text] [Related]
4. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
[TBL] [Abstract][Full Text] [Related]
5. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
[TBL] [Abstract][Full Text] [Related]
6. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
[TBL] [Abstract][Full Text] [Related]
7. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
8. Pharmacometrics-guided drug development of antihyperhidrosis agents.
Mehrotra S; Schmith VD; Dumitrescu TP; Gobburu J
J Clin Pharmacol; 2015 Nov; 55(11):1256-67. PubMed ID: 25939678
[TBL] [Abstract][Full Text] [Related]
9. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
[TBL] [Abstract][Full Text] [Related]
10. Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature.
Nofal E; Salem S; Khashaba SA
Dermatol Surg; 2022 Aug; 48(8):843-848. PubMed ID: 35917265
[TBL] [Abstract][Full Text] [Related]
11. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Artzi O; Loizides C; Zur E; Sprecher E
Acta Derm Venereol; 2017 Oct; 97(9):1120-1124. PubMed ID: 28654131
[TBL] [Abstract][Full Text] [Related]
12. The use of topical glycopyrrolate in the treatment of hyperhidrosis.
Seukeran DC; Highet AS
Clin Exp Dermatol; 1998 Sep; 23(5):204-5. PubMed ID: 10233600
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Hotline: Topical glycopyrrolate: a successful treatment for craniofacial hyperhidrosis and eccrine hidrocystomas.
Garnacho Saucedo GM; Moreno Jiménez JC; Jiménez Puya R; Rodríguez Bujaldon A
Dermatol Ther; 2010; 23(1):94-7. PubMed ID: 20136914
[TBL] [Abstract][Full Text] [Related]
14. Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use.
Lamb YN
Clin Drug Investig; 2019 Nov; 39(11):1141-1147. PubMed ID: 31571127
[TBL] [Abstract][Full Text] [Related]
15. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis.
Paller AS; Shah PR; Silverio AM; Wagner A; Chamlin SL; Mancini AJ
J Am Acad Dermatol; 2012 Nov; 67(5):918-23. PubMed ID: 22405644
[TBL] [Abstract][Full Text] [Related]
16. A medical alternative to the treatment of compensatory sweating.
Cladellas E; Callejas MA; Grimalt R
Dermatol Ther; 2008; 21(5):406-8. PubMed ID: 18844718
[TBL] [Abstract][Full Text] [Related]
17. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
[TBL] [Abstract][Full Text] [Related]
18. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
Nwannunu CE; Limmer AL; Coleman K; Shah R; Patel RR; Mui UN; Tyring SK
Skin Therapy Lett; 2019 Mar; 24(2):1-3. PubMed ID: 30970203
[TBL] [Abstract][Full Text] [Related]
19. [Topical glycopyrrolate in craniofacial hyperhidrosis].
Callejas MA; Grimalt R
Med Clin (Barc); 2008 Jun; 131(4):157. PubMed ID: 18601830
[No Abstract] [Full Text] [Related]
20. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Hebert AA; Glaser DA; Green L; Hull C; Cather J; Drew J; Gopalan R; Pariser DM
Pediatr Dermatol; 2020 May; 37(3):490-497. PubMed ID: 32147881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
